Fourth Asian Pacific Conference:
Perspectives in Lung Cancer
3-4 September 2010
Hong Kong, China
Friday, 3 September 2010
8:15
Opening remarks
Session I
State-of-the-art in surgery
8:30
The art of radical surgery
David Harpole, Jr, MD
8:55
The art of minimal invasive surgery
Masahiro Tsuboi, MD
9:20
EBUS versus mediastinoscopy
Yuk Pui Innes Wan, MBChB, FCSHK, FRCS Ed, FHKAM
Session II
Tobacco and carcinogenesis
9:45
Tobacco control in Asia
Daniel SY Ho, PhD, MPH
10:20
Carcinogenesis of lung cancer: Smoker vs non-smoker
George G. Chen, MB, PhD
10:45
Coffee break
Session III
State-of-the-art radiotherapy
11:15
Novel radiotherapy technology
Min Fan, MD
11:40
Sterotactic radiotherapy for resectable lung cancer
Hiroshi Onishi, MD
12:05
Sterotactic and respiratory gated radiotherapy: Local experience
WK Tsang, MD, FRCR
12:30
Lunch break
Keynote lecture
13:30
Clinical trial on molecular targeting agent: What is right and what is wrong?
Made possible by Astra-Zeneca
Frances A. Shepherd, MD, FRCPC
Case presentation I
14:10
Case presentation
Victor Ho Fun Lee, MBBD
14:25
Case presentation
Min Fan, MD
Session IV
Gene signature and biomarkers
14:40
Gene signature for chemotherapy
Giorgio V Scagliotti, MD, PhD
15:15
Metagene or magic gene
David Harpole, Jr, MD
15:30
Coffee break
Session V
Stage III disease
16:15
Optimal radiotherapy for stage III NSCLC
Ming Chen, MD
16:40
Optimal combined modality for stage III NSCLC
Wilfried Eberhardt, MD
17:05
Adjourn
Saturday 4 September 2010
Session VI
State-of-the-art in chemotherapy
8:30
Novel development in cytotoxic chemotherapy
Mark Vincent, MD, ChB
8:55
Combination of chemotherapy with molecular target therapy:
A good idea that is not so good
Tony Mok, MD
9:20
Patient selection for maintenance therapy
Keunchil Park, MD
Session VII
Novel targets
9:35
MAGE A3
Giovannit Selvaggi, MD
9:50
ELM-4 ALK: Clinical data
Tetsuya Mitsudomi, MD
10:05
ELM-4 ALK: Defining a biomarker
Yi-Long Wu, MD
10:20
IGF-R
KC Lam, MD
10:45
Irreversible EGFR TKI
James Chih-HsinYang, MD, PhD
11:00
Vascular disrupting agent and VEGF TKIs
Nick Pavlakis, MD
11:15
Coffee break
Session VIII
State-of-the-art diagnosis
11:45
Radial EBUS and pleuroscopy for diagnosis of lung cancer
Matthew Wong, MD
12:05
PET-Scan, MRI, or CT scan: Which is a better tool for early/late stage NSCLC?
Michael Boyer, MB, BS, PhD
12:25
The challenge of histologic diagnosis in lung cancer: Is adenocarcinoma really an
adenocarcinoma?
KF To, MD
Case presentation II
12:50
Case presentation
Maya Gottfried, MD
13:05
Case presentation
Linda Leung, MBBS, MRCP, FHKCP, FHKAM
13:15
Lunch break
Session IX
The unfinished EGFR story
14:15
Cost-effectiveness of EGFR TKI
Gilberto Lopes, MD
14:30
Detecting EGFR mutation in plasma: DHPLC
Jie Wang, MD, PhD
14:45
Detecting EGFR mutation in plasma: Digital PCR
Allen KC Chan, MD, PhD
15:00
EGFR TKI resistance
Lu Shun, MD, PhD
15:15
Pharmacokinetics of EGFR TKI and treatment out come
Zhang Li, MD
15:30
Coffee break
Session X
Research and development
15:50
The art and science of phase I study
Brigette Ma, MD, FRCP
16:10
Getting published in a high impact journal
Anthony KC Chan, MD
16:20
Current status of lung cancer research in Asia
Sumitra Thongprasert, MD
Current status of lung cancer research in China
Yi-Long Wu, MD
Current status of lung cancer research in India
Gouri Shankar Bhattacharyya, MD, MRCP, DNB, PhD
17:00
Adjourn
